Publication: 3120

Publication: 3120

Androgen Decline and Survival During Docetaxel Therapy in metastatic Castration Resistant Prostate Cancer (mCRPC)

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: Prostate Cancer Prostatic Dis vol 23 (1) 66-73

Year:: 2020
Type:: Manuscript
Funding:: NCTN
Endpoint:: Secondary-not-in-original
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: pmc-release

Note:

Methodological:: No
Biospecimen:: Yes
SDC:: Yes
Book Volume:: 9

Parents:: 2835
Children:: None

Program:: OGC
Primary Committee:: GU
Sec. Committees:

Pharmas:: Genentech
Grants:: R21 CA195424-01, U10CA180821, U10CA180882, W81XWH-15-1-0467; P30 CA 008748, U24CA196171

Corr. Author:
Authors:: Charles J Ryan Sandipan Dutta William K Kelly Carly Russell Eric J. Small Michael J. Morris Mary-Ellen Taplin Susan Halabi

Networks:: CA824, LAPS-MA036, LAPS-NY016, MN022

Study: CALGB-90401
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords:: Androgens, Metastatic Castration-Resistant Prostate Cancer, Testosterone, Prognostic biomarker Docetaxel